Alternative Indications for Bisphosphonate Therapy

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 5 SUPPL., 2009, Pages 27-34

  Landesberg, Regina ^a   Eisig, Sidney ^b   Fennoy, Ilene ^c   Siris, Ethel ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b New York Presbyterian Hospital   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; PAMIDRONIC ACID; STEROID; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE PAIN; CASE REPORT; DRUG INDICATION; FEMALE; FIBROUS DYSPLASIA; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; GIANT CELL GRANULOMA; GIANT CELL TUMOR; HEADACHE; HISTOPATHOLOGY; HUMAN; IMPLANT; JAW OSTEONECROSIS; MALE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOMYELITIS;

ADOLESCENT; ALVEOLAR BONE LOSS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DENTAL IMPLANTS; DIPHOSPHONATES; FEMALE; FIBROUS DYSPLASIA OF BONE; GAUCHER DISEASE; GIANT CELL TUMORS; HUMANS; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; OSTEOMYELITIS; YOUNG ADULT;

EID: 64249095088     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2008.12.006     Document Type: Article

References (106)

1. Neville B.W., Damm D.D., Allen C.M., et al. Oral and Maxillofacial Pathology. (ed 3) (2008), WB Sauders, Philadelphia, PA
2. Regezi J.A., Sciubba J., and Jordan R. Oral Pathology: Clinical Pathologic Correlations. (ed 5) (2007), WB Saunders, Philadelphia, PA
3. Sapp J.P., Eversole L.R., and Wysocki G.P. Contemporary Oral and Maxillofacial Pathology. (ed 2) (2003), Mosby, St Louis, MO
4. Kaugars G.E., Niamtu III J., and Svirsky J.A. Cherubism: Diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors. Oral Surg Oral Med Oral Pathol 73 (1992) 369
5. Auclair P.L., Cuenin P., Kratochvil F.J., et al. A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor. Oral Surg Oral Med Oral Pathol 66 (1988) 197
6. O'Malley M., Pogrel M.A., Stewart J.C., et al. Central giant cell granulomas of the jaws: Phenotype and proliferation-associated markers. J Oral Pathol Med 26 (1997) 159
7. Sezer B., Koyuncu B., Gomel M., et al. Intralesional corticosteroid injection for central giant cell granuloma: A case report and review of the literature. Turk J Pediatr 47 (2005) 75
8. Harris M. Central giant cell granulomas of the jaws regress with calcitonin therapy. Br J Oral Maxillofac Surg 31 (1993) 89
9. de Lange J., Rosenberg A.J., van den Akker H.P., et al. Treatment of central giant cell granuloma of the jaw with calcitonin. Int J Oral Maxillofac Surg 28 (1999) 372
10. Pogrel M.A. Calcitonin therapy for central giant cell granuloma. J Oral Maxillofac Surg 61 (2003) 649
11. Pogrel M.A. Discussion: Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg 65 (2007) 2024
12. Kaban L.B., Mulliken J.B., Ezekowitz R.A., et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 103 6 Pt 1 (1999) 1145
13. Kaban L.B., Troulis M.J., Ebb D., et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 60 (2002) 1103
14. Kaban L.B., and Dodson T.B. Management of giant cell lesions. Int J Oral Maxillofac Surg 35 (2006) 1074
15. Kaban L.B., Troulis M.J., Wilkinson M.S., et al. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg 65 (2007) 2018
16. Goldman K.E., Marshall M.K., Alessandrini E., et al. Complications of alpha-interferon therapy for aggressive central giant cell lesion of the maxilla. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 (2006) 285
17. Balke M., Schremper L., Gebert C., et al. Giant cell tumor of bone: Treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134 (2008) 969
18. Tse L.F., Wong K.C., Kumta S.M., et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study. Bone 42 (2008) 68
19. Sillence D.O., Senn A., and Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16 (1979) 101
20. Vallo A., Rodriguez-Leyva F., and Rodriguez S.J. Osteogenesis imperfecta: Anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 95 (2006) 332
21. Byers P.H., Wallis G.A., and Willing M.C. Osteogenesis imperfecta: Translation of mutation to phenotype. J Med Genet 28 (1991) 433
22. Glorieux F.H., Rauch F., Plotkin H., et al. Type V osteogenesis imperfecta: A new form of brittle bone disease. J Bone Miner Res 15 (2000) 1650
23. Glorieux F.H., Ward L.M., Rauch F., et al. Osteogenesis imperfecta type VI: A form of brittle bone disease with a mineralization defect. J Bone Miner Res 17 (2002) 30
24. Ward L.M., Rauch F., Travers R., et al. Osteogenesis imperfecta type VII: An autosomal recessive form of brittle bone disease. Bone 31 (2002) 12
25. Glorieux F.H., Bishop N.J., Plotkin H., et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339 (1998) 947
26. Roelofs A.J., Thompson K., Gordon S., et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 12 (2006) 6222s
27. Russell R.G. Bisphosphonates: Mode of action and pharmacology. Pediatrics 119 suppl 2 (2007) S150
28. Russell R.G., Xia Z., Dunford J.E., et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117 (2007) 209
29. Plotkin L.I., Weinstein R.S., Parfitt A.M., et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104 (1999) 1363
30. Rauch F. The growing skeleton is a busy place-Can biochemical bone markers keep track of the action?. J Pediatr 153 (2008) 454
31. Andiran N., Alikasifoglu A., Gonc N., et al. Cyclic pamidronate therapy in children with osteogenesis imperfecta: Results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 21 (2008) 63
32. Cabral de Menezes Filho H., Rodrigues J.M., Radonsky V., et al. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta. Horm Res 68 suppl 5 (2007) 207
33. DiMeglio L.A., and Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21 (2006) 132
34. DiMeglio L.A., Ford L., McClintock C., et al. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 18 (2005) 43
35. Grissom L.E., Kecskemethy H.H., Bachrach S.J., et al. Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol 35 (2005) 511
36. Land C., Rauch F., Montpetit K., et al. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 148 (2006) 456
37. Land C., Rauch F., Travers R., et al. Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment. Bone 40 (2007) 638
38. Letocha A.D., Cintas H.L., Troendle J.F., et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20 (2005) 977
39. Lowing K., Astrom E., Oscarsson K.A., et al. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr 96 (2007) 1180
40. Munns C.F., Rauch F., Travers R., et al. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res 20 (2005) 1235
41. Munns C.F., Rauch F., Zeitlin L., et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19 (2004) 1779
42. Plotkin H., Rauch F., Bishop N.J., et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85 (2000) 1846
43. Poyrazoglu S., Gunoz H., Darendeliler F., et al. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop 28 (2008) 483
44. Rauch F., Munns C., Land C., et al. Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. J Clin Endocrinol Metab 91 (2006) 1268
45. Senthilnathan S., Walker E., and Bishop N.J. Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child 93 (2008) 398
46. Zeitlin L., Rauch F., Travers R., et al. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V. Bone 38 (2006) 13
47. Glorieux F.H. Experience with bisphosphonates in osteogenesis imperfecta. Pediatr 119 suppl 2 (2007) S163
48. Bembi B., Parma A., Bottega M., et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131 (1997) 622
49. Land C., Rauch F., Munns C.F., et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone 39 (2006) 901
50. Kamoun-Goldrat A., Ginisty D., and Le M.M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 116 (2008) 195
51. Rauch F., Travers R., Munns C., et al. Sclerotic metaphyseal lines in a child treated with pamidronate: Histomorphometric analysis. J Bone Miner Res 19 (2004) 1191
52. Damiani D. Metaphyseal sclerosis associated with bisphosphonate therapy. J Pediatr Endocrinol Metab 20 (2007) 1167
53. Land C., Rauch F., and Glorieux F.H. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21 (2006) 374
54. Malmgren B., Astrom E., and Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37 (2008) 196
55. Schwartz S., Joseph C., Iera D., et al. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: A case series. J Can Dent Assoc 74 (2008) 537
56. McCarthy E.A., Raggio C.L., Hossack M.D., et al. Alendronate treatment for infants with osteogenesis imperfecta: Demonstration of efficacy in a mouse model. Pediatr Res 52 (2002) 660
57. Unal E., Abaci A., Bober E., et al. Oral alendronate in osteogenesis imperfecta. Indian Pediatr 42 (2005) 1158
58. Seikaly M.G., Kopanati S., Salhab N., et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25 (2005) 786
59. Vyskocil V., Pikner R., and Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 72 (2005) 416
60. Cho T.J., Choi I.H., Chung C.Y., et al. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop 25 (2005) 607
61. Ward L.M., Denker A.E., Porras A., et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 90 (2005) 405
62. Madenci E., Yilmaz K., Yilmaz M., et al. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol 12 (2006) 53
63. Akcay T., Turan S., Guran T., et al. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr 45 (2008) 105
64. Chevrel G., Schott A.M., Fontanges E., et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: A 3-year randomized placebo-controlled trial. J Bone Miner Res 21 (2006) 300
65. Shah I., and Johari A. Oral bisphosphonate treatment for osteogenesis imperfecta-An Indian perspective. Ann Trop Paediatr 27 (2007) 39
66. Chapurlat R.D., and Meunier P.J. Fibrous dysplasia of bone. Baillieres Best Pract Res Clin Rheumatol 14 (2000) 385
67. Stephenson R.B., London M.D., Hankin F.M., et al. Fibrous dysplasia. An analysis of options for treatment. J Bone Joint Surg Am 69 (1987) 400 1987
68. Yamamoto T. Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome. J Bone Miner Metab 24 (2006) 7
69. Chapurlat R.D., and Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol 22 (2008) 55
70. Chapurlat R.D. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 21 suppl 2 (2006) P114
71. Chapurlat R.D., Delmas P.D., Liens D., et al. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12 (1997) 1746
72. Chapurlat R.D., Hugueny P., Delmas P.D., et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment. Bone 35 (2004) 235
73. Parisi M.S., Oliveri B., and Mautalen C.A. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 33 (2003) 582
74. Lane J.M., Khan S.N., O'Connor W.J., et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 382 (2001) 6
75. Hempel J.M., Karkos P.D., and Issing W.J. Fibrous dysplasia of the frontal bone. Ear Nose Throat J 85 (2006) 654
76. Bembi B., and Deegan P. Gaucher disease: Improving management. Acta Paediatr Suppl 97 (2008) 81
77. Wenstrup R.J., Roca-Espiau M., Weinreb N.J., et al. Skeletal aspects of Gaucher disease: A review. Br J Radiol 75 suppl 1 (2002) A2
78. Wenstrup R.J., Bailey L., Grabowski G.A., et al. Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104 (2004) 1253
79. Harinck H.I., Bijvoet O.L., van der Meer J.W., et al. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet 8401 (1984) 513
80. Ciana G., Cuttini M., and Bembi B. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med 337 (1997) 712
81. Samuel R., Katz K., Papapoulos S.E., et al. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 94 (1994) 385
82. Giedion A., Holthusen W., Masel L.F., et al. Subacute and chronic "symmetrical" osteomyelitis. Ann Radiol (Paris) 15 (1992) 329
83. Carr A.J., Cole W.G., Roberton D.M., et al. Chronic multifocal osteomyelitis. J Bone Joint Surg Br 75 (1993) 582
84. Gamble J.G., and Rinsky L.A. Chronic recurrent multifocal osteomyelitis: A distinct clinical entity. J Pediatr Orthop 6 (1984) 579
85. Chun C.S. Chronic recurrent multifocal osteomyelitis of the spine and mandible: Case report and review of the literature. Pediatrics 113 (2004) e380
86. Beretta-Piccoli B.C., Sauvain M.J., Gal I., et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: A report of ten cases and review of the literature. Eur J Pediatr 159 (2000) 594
87. Suei Y., Tanimoto K., Taguchi A., et al. Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis. One entity or two. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80 (1995) 401
88. Simm P.J., Allen R.C., and Zacharin M.R. Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis. J Pediatr 152 (2008) 571
89. Gleeson H., Wiltshire E., Briody J., et al. Childhood chronic recurrent multifocal osteomyelitis: Pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol 35 (2008) 707
90. Compeyrot-Lacassagne S., Rosenberg A.M., Babyn P., et al. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol 34 (2007) 1585
91. Yamazaki Y., Satoh C., Ishikawa M., et al. Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 (2007) 67
92. Montonen M., Kalso E., Pylkkären L., et al. Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible. Int J Oral Maxillofac Surg 30 (2001) 313
93. Jacobs J.J., Hallab N.J., Urban R.M., et al. Wear particles. J Bone Joint Surg Am 88 suppl 2 (2006) 99
94. Hirakawa K., Jacobs J.J., Urban R., et al. Mechanisms of failure of total hip replacements: Lessons learned from retrieval studies. Clin Orthop Relat Res 420 (2004) 10
95. Venesmaa P.K., Kröger H.P., Miettinen H.J., et al. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study. J Bone Miner Res 16 (2001) 2126
96. Wang C.J., Wang J.W., Weng L.H., et al. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am 85-A (2003) 2121
97. Eberhardt C., Stumpf U., Brankamp J., et al. Osseointegration of cementless implants with different bisphosphonate regimens. Clin Orthop Relat Res 447 (2006) 195
98. Nakamura Y., Hayashi K., Abu-Ali S., et al. Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats. J Bone Joint Surg Am 90 (2008) 824
99. Kurth A.H., Eberhardt C., Müller S., et al. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 37 (2005) 204
100. Wermelin K., Tengvall P., and Aspenberg P. Surface-bound bisphosphonates enhance screw fixation in rats-Increasing effect up to 8 weeks after insertion. Acta Orthop 78 (2007) 385
101. Stadelmann V.A., Gauthier O., Terrier A., et al. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater 16 (2008) 10
102. Suratwala S.J., Cho S.K., van Raalte J.J., et al. Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am 90 (2008) 2189
103. Wermelin K., Suska F., Tengvall P., et al. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone 42 (2008) 365
104. Iwase M., Kim K.J., Kobayashi Y., et al. A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles. J Orthop Res 20 (2002) 499
105. Astrand J., and Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates: High doses are needed in rats. Acta Orthop Scand 73 (2002) 24
106. Tsutsumi R., Hock C., Bechtold C.D., et al. Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. J Orthop Res 26 (2008) 1340